

# Non-Small Cell Lung Cancer Market Size, Company Revenue Share, Key Drivers & Trend Analysis, 2022–2030

*Market Size – USD 7.41 Billion in 2021,  
Market Growth – at a CAGR of 6.8%,  
Market Trends – Rising prevalence of lung cancer*

NEW YORK, NY, UNITED STATES, May 6, 2022 /EINPresswire.com/ -- The global [Non-Small Cell Lung Cancer \(NSCLC\) market](#) size is expected to reach USD 13.51 Billion in 2030 and

register a revenue CAGR of 6.8% over the forecast period, according to latest report by Reports and Data. Excessive consumption of tobacco, increase in active and passive smokers, and exposure to high levels of pollution are key factors propelling market revenue growth of NSCLC.

NSCLC accounts for a significant percentage of lung cancer cases across the world, and this high number has encouraged market players to focus on development of new therapies and improving efficacy of existing medicines for the disease. Lung cancer is one of the most common malignancies and results in a significant number of deaths globally. This has created a need to treat the disease and reduce mortality rate.

Expansion of NSCLC market is further aided by an increase in frequency of diagnosis of non-small cell lung cancer and increased awareness regarding the disease in developed and emerging countries. This, combined with increased investment in R&D by pharmaceutical companies and rapid adoption of new and better healthcare technologies is driving market revenue growth of NSCLC market. Moreover, increased adoption of immunotherapy in developing countries due to improved patient outcomes because of efficient treatment is expected to drive market revenue growth.

Get a sample of the report @ <https://www.reportsanddata.com/sample-enquiry-form/1475>

Some Key Highlights from the Report

In February 2021, the U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor Libtayo



Reports And Data

for first-line treatment of patients with advanced NSCLC whose tumors have high PD-L1 expression (tumor proportion score  $\geq 50\%$ ), as determined by FDA-approved test

Adenocarcinoma segment accounted for largest revenue share in 2021, as it is most common type of lung cancer and has a high rate of incidence globally. About 40% of all cases of lung cancers are diagnosed with Adenocarcinoma. It usually occurs when lung cells proliferate abnormally to form a tumorous growth. Lung adenocarcinoma is most common cell type in females (smokers or non-smokers) and in non-smoking males. Incidence has been increasing in younger cohorts of males and females and has become a major cause of concern.

Surgery segment revenue is expected to register a steady growth rate during the forecast period, as surgery performed at an early stage is the best time to cure NSCLC. Patients diagnosed with Stage 0 and Stage 1 NSCLC are provided surgical treatments such as segmentectomy and lobectomy which have proven success rates.

Angiogenesis inhibitor accounted for a significant market revenue share in 2021. Segment growth is attributed to increasing demand for highly effective and more targeted therapies in both established as well as emerging economies such as the U.S., India, Japan, and Europe among others.

Market in North America accounted for largest revenue share in 2021 due to increasing support from the U.S. Government for developing therapies and drugs to treat different types of cancer. Availability of state-of-the-art research facilities and access to advanced testing equipment helps with successful research, which is also contributing to market growth.

Market in Europe accounted for second-largest revenue share in 2021 due to increased R&D initiatives for development of advanced therapeutics. Moreover, presence of leading companies such as Novartis, AstraZeneca, Sanofi, and Roche are fueling growth of market.

Major companies in global market report include Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Novartis AG, Boehringer Ingelheim International GmbH, F.Hoffmann-La Roche Ltd, Merck KGaA, Sanofi, and Astellas Pharma Inc.

Download Summary @ <https://www.reportsanddata.com/download-summary-form/1475>

The report also offers detailed insights about market segmentation based on type, application and regional bifurcation:

Non-Small Cell Lung Cancer Market Segmentation:

Type Outlook (Revenue, USD Billion; 2019-2030)

Adenocarcinoma

Squamous cell carcinoma  
Large cell carcinoma  
Others

Therapy Outlook (Revenue, USD Billion; 2019-2030)

Chemotherapy  
Targeted therapy  
Surgery  
Radiotherapy  
Laser therapy  
Photodynamic therapy  
Immunotherapy  
Others

Drug Class Outlook (Revenue, USD Billion; 2019-2030)

Angiogenesis Inhibitor  
Epidermal Growth Factor Receptor Inhibitor  
Kinase Inhibitor  
Microtubule Stabilizer  
Folate Antimetabolites  
PD-1/ PD-L1 Inhibitor  
Others

Regional Outlook:

North America  
Europe  
Asia Pacific  
Latin America  
Middle East & Africa

Request a customization of the report @ <https://www.reportsanddata.com/request-customization-form/1475>

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries,

including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Tushar Rajput  
Reports and Data  
+18008193052 ext.

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/571385561>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.